A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes
暂无分享,去创建一个
[1] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[2] F. Paul,et al. Perivascular spaces--MRI marker of inflammatory activity in the brain? , 2008, Brain : a journal of neurology.
[3] A J Thompson,et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[4] N. Richert. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.
[5] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[6] Massimo Filippi,et al. MR Spectroscopy in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[7] Frederik Barkhof,et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. , 2005, Radiology.
[8] F. Barkhof,et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.
[9] M Filippi,et al. Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.
[10] G. Fein,et al. Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.
[11] J H Simon,et al. Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.
[12] P. Matthews,et al. Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.
[13] P M Matthews,et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.
[14] J S Wolinsky,et al. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. , 2001, Multiple sclerosis.
[15] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[16] Heinrich Lanfermann,et al. Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results , 2006, European Radiology.
[17] M Rovaris,et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis , 2004, Neurology.
[18] R. Rudick,et al. Impact of Disease‐Modifying Therapies on Brain and Spinal Cord Atrophy in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[19] J. denBoer,et al. A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging , 1995, Multiple sclerosis.
[20] A. Thompson,et al. Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis , 2009, Multiple sclerosis.
[21] M. Filippi,et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.
[22] P. Matthews,et al. Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.
[23] F. Barkhof,et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.
[24] H. Bruhn,et al. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.
[25] P M Matthews,et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.
[26] M. Rovaris,et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. , 2006, Brain : a journal of neurology.
[27] Massimo Filippi,et al. European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.
[28] F Barkhof,et al. MR venography of multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[29] P M Matthews,et al. Proton MR spectroscopy in multiple sclerosis. , 2000, Neuroimaging clinics of North America.
[30] P M Matthews,et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.
[31] Robert Zivadinov,et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome , 2008, Journal of Neurology.
[32] Frederik Barkhof,et al. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.
[33] F. Paul,et al. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis , 2009, Neurology.
[34] F Barkhof,et al. Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.
[35] D. Auer,et al. Spinal Cord Imaging in Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[36] G. Comi,et al. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS , 2008, Journal of Neurology.
[37] Frauke Zipp,et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis , 2009, Annals of neurology.
[38] J. Wuerfel,et al. CNS‐irrelevant T‐cells enter the brain, cause blood–brain barrier disruption but no glial pathology , 2007, The European journal of neuroscience.
[39] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[40] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[41] G J Barker,et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. , 2005, Brain : a journal of neurology.
[42] David H. Miller,et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.
[43] O. Khan,et al. Long‐Term Study of Brain 1H‐MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long‐Term 1H‐MRS Monitoring in Multiple Sclerosis , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[44] J. Coyle,et al. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.
[45] Frauke Zipp,et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. , 2004, Brain : a journal of neurology.
[46] F. Barkhof,et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial , 2008, The Lancet Neurology.
[47] Richard H. Price,et al. Black Holes , 1997 .
[48] C. Kuhl,et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? , 2006, AJNR. American journal of neuroradiology.
[49] Massimo Filippi,et al. Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.